Search our Database of Scientific Publications and Authors

I’m looking for a

    4697 results match your criteria Bullous Pemphigoid

    1 OF 94

    [Sudden-onset bullous pemphigoid in a 12-year-old child].
    Arch Pediatr 2017 Apr 17. Epub 2017 Apr 17.
    Service de dermatologie et de vénéréologie, CHU Ibn Sina, Rabat, Maroc.
    Bullous pemphigoid (BP) is an acquired autoimmune disease that mainly affects the elderly. It is very rare in children. We report a sudden polymorphic case of BP in a 12-year-old child. Read More

    Oral Lichenoid Reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings.
    J Eur Acad Dermatol Venereol 2017 Apr 17. Epub 2017 Apr 17.
    Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Immune checkpoint inhibitors targeting the programmed cell death receptor-1 (PD-1) or its ligand (PD-L1) show broad activity across different tumor types and currently represent one of the keystones of cancer management. Dermatologic toxicities are one of the most frequent immune-related adverse events (irAEs) induced by these new monoclonal antibodies. Maculopapular rash, pruritus, exacerbation of psoriasis or more specific autoimmune disorders (e. Read More

    Complement-independent blistering mechanisms in bullous pemphigoid.
    Exp Dermatol 2017 Apr 18. Epub 2017 Apr 18.
    Department of Dermatology, Hokkaido University Graduate School of Medicine.
    Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disease that clinically demonstrates tense blisters with widespread erythema, histologically demonstrates subepidermal blistering and immunologically demonstrates the presence of circulating autoantibodies against hemidesmosomal molecules. Complement activation has long been regarded as necessary for the generation of the BP. However, certain evidence has recently come to support non-complemental blistering mechanisms. Read More

    A distinct cutaneous microbiota pofile in autoimmune bullous disease patients.
    Exp Dermatol 2017 Apr 18. Epub 2017 Apr 18.
    Lübeck Institute of Experimental Dermatology (LIED), University of Lübeck, Lübeck, Germany.
    Bullous Pemphigoid (BP) is the most common autoimmune blistering disease in Europe. As both the incidence of the disease and the relative proportion of the elderly population continue to rise, it represents a significant medical burden. Whereas some progress has been achieved in defining genetic risk factors for autoimmune blistering diseases, no environmental agent has been conclusively identified. Read More

    Oesophageal involvement in 26 consecutive patients with mucous membrane pemphigoid.
    Br J Dermatol 2017 Apr 18. Epub 2017 Apr 18.
    Department of Dermatology and Referral Center for Auto-Immune Bullous Diseases, Avicenne Hospital, APHP, University Paris 13, 93009, Bobigny, France.
    Background: Oesophageal involvement of mucous membrane pemphigoid (MMP) has not yet been thoroughly described.

    Objectives: This study was undertaken to systematically characterise the endoscopic lesions of a series of patients with oesophageal symptoms seen in a referral centre for autoimmune bullous diseases.

    Methods: Clinical, endoscopic and immunological findings of consecutively referred MMP patients with oesophageal involvement, systemic and endoscopic treatments and follow-up, are described. Read More

    Successful Treatment of a Bullous Pemphigoid Patient with Rituximab Who Was Refractory to Corticosteroid and Omalizumab Treatments.
    Case Rep Dermatol 2017 Jan-Apr;9(1):38-44. Epub 2017 Feb 10.
    Akdeniz University Faculty of Medicine, Dermatology and Venereology Department, Antalya, Turkey.
    Omalizumab is a humanized monoclonal antibody which is an FDA-approved treatment of severe allergic asthma and inhibits IgE binding to FcεRI. According to increasing evidence of IgE inhibition, omalizumab was suggested as a therapeutic approach for bullous pemphigoid (BP). Rituximab has been reported to be effective in various autoimmune diseases, including autoimmune bullous dermatoses. Read More

    A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial.
    Health Technol Assess 2017 Mar;21(10):1-90
    Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK.
    Background: Bullous pemphigoid (BP) is an autoimmune blistering skin disorder with increased morbidity and mortality in the elderly.

    Objectives: To evaluate the effectiveness, safety and cost-effectiveness of a strategy of initiating BP treatment with oral doxycycline or oral prednisolone. We hypothesised that starting treatment with doxycycline gives acceptable short-term blister control while conferring long-term safety advantages over starting treatment with oral prednisolone. Read More

    Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016.
    J Invest Dermatol 2017 Apr 5. Epub 2017 Apr 5.
    Institute of Anatomy and Cell Biology, Ludwig-Maximilians-Universität, Munich, Germany.
    Autoimmune blistering diseases are a heterogeneous group of about a dozen complex disorders that are characterized by intraepidermal (pemphigus) and subepidermal blistering (pemphigoid diseases and dermatitis herpetiformis). The Pathogenesis of Pemphigus and Pemphigoid Meeting, organized by the Departments of Dermatology in Lübeck and Marburg and the Institute of Anatomy and Cell Biology, Munich, was held in September 2016 in Munich. The meeting brought together basic scientists and clinicians from all continents dedicating their work to autoimmune blistering diseases. Read More

    Photodynamic Therapy Effective for the Treatment of Actinic Keratosis and Basal Cell Carcinoma in Bullous Pemphigoid Patients.
    Photodiagnosis Photodyn Ther 2017 Mar 31. Epub 2017 Mar 31.
    Department of Dermatology, University of Alabama at Birmingham, United States. Electronic address:
    Treating skin cancers and extensive actinic keratosis in patients with bullous pemphigoid (BP) can be challenging. Treatment options pose unique risks in these patients as surgical wounds can have delayed wound healing and photodynamic therapy (PDT) may exacerbate their blistering disease. We report the successful use of PDT to treat actinic keratosis and skin cancers in two patients with BP, both of whom had excellent response to PDT and tolerated treatment without any bullous disease flares. Read More

    Amino acid duplication in the coiled-coil structure of collagen XVII alters its maturation and trimerization causing mild junctional epidermolysis bullosa.
    Hum Mol Genet 2017 Feb;26(3):479-488
    Department of Dermatology, Medical Center-University of Freiburg, Freiburg, Germany.
    The function and stability of collagens depend on the accurate triple helix formation of three distinct polypeptide chains. Disruption of this triple-helical structure can result in connective-tissue disorders. Triple helix formation is thought to depend on three-stranded coiled-coil oligomerization sites within non-collagenous domains. Read More

    Systemic Lupus Erythematosus and Bullous Pemphigoid with Dramatic Response to Dapsone.
    Am J Case Rep 2017 Mar 29;18:317-319. Epub 2017 Mar 29.
    NEUROFARBA Department, University of Florence and AOU Meyer, Florence, Italy.
    BACKGROUND Bullous pemphigoid is an autoimmune blistering disease, with relapses, isolated or associated with other autoimmune diseases such as systemic lupus erythematosus (SLE). Joint manifestations rapidly respond to small or moderate doses of corticosteroids, whereas skin manifestations usually respond to antimalarial drugs. CASE REPORT We describe the clinical case of an 11-year-old girl with SLE. Read More

    TWEAK/Fn14 activation contributes to the pathogenesis of bullous pemphigoid.
    J Invest Dermatol 2017 Mar 25. Epub 2017 Mar 25.
    Department of Dermatology, The Second Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, China. Electronic address:
    Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) participates in various cellular effects by engaging its receptor of fibroblast growth factor inducible 14 (Fn14). Increased levels of soluble TWEAK are associated with systemic autoimmunity in patients with lupus erythematosus, rheumatoid arthritis or dermatomyositis. However, the role of TWEAK in bullous pemphigoid (BP) remains unknown. Read More

    Case of bullous pemphigoid coexisting with anti-desmoglein autoantibodies.
    J Dermatol 2017 Mar 24. Epub 2017 Mar 24.
    Department of Dermatology, Shimane University Faculty of Medicine, Izumo, Japan.
    A 79-year-old Japanese woman had clinical and histopathological features of bullous pemphigoid, while direct immunofluorescence test revealed C3 and immunoglobulin G depositions in the lower cell surfaces of the epidermis in addition to those in the dermoepidermal junction. Chemiluminescent enzyme immunoassays were positive for desmoglein-1 and -3 antibodies in addition to anti-BP180 antibodies. In an immunoblotting study, antibodies against both 180-kDa bullous pemphigoid antigen and 130-kDa pemphigus vulgaris antigen were detected. Read More

    Human Orf complicated by Epidermolysis Bullosa Acquisita.
    Br J Dermatol 2017 Mar 24. Epub 2017 Mar 24.
    Dermatology Department, Saint-Louis Hospital, Paris, France.
    Orf is a DNA parapoxvirus transmitted to humans by contact with infected goats and sheep. Many complications have been reported after Orf infection including erythema multiforme. A few cases of auto-immune bullous dermatosis complicating Orf disease have been reported to date, usually characterized by tense blisters eruptions with or without mucosal involvement, linear deposition of C3, IgG and/or IgA along the basement membrane and negativity of indirect immunofluorescence analysis and ELISA assays (performed in 4 of 11 reported cases) against target antigens of bullous pemphigoid, mucous membrane pemphigoid or epidermolysis bullosa acquisita, except one case of mucosal pemphigoid with antilaminin-332 antibodies. Read More

    Skin disorders in Parkinson's disease: potential biomarkers and risk factors.
    Clin Cosmet Investig Dermatol 2017 9;10:87-92. Epub 2017 Mar 9.
    Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
    Parkinson's disease (PD) is one of the most common neurodegenerative disorders, characterized by a symptom triad comprising resting tremor, rigidity, and akinesia. In addition, non-motor symptoms of PD are well recognized and often precede the overt motor manifestations. Cutaneous manifestations as markers of PD have long been discussed, and cumulative evidence shows an increased prevalence of certain dermatological disorders in PD. Read More

    Bullous pemphigoid of infancy - report and review of infantile and pediatric bullous pemphigoid.
    Dermatol Online J 2017 Feb 16;23(2). Epub 2017 Feb 16.
    Department of Dermatology, Coimbra Hospital and University Centre, Coimbra, Portugal.
    A 4-month-old infant was observed with an acute itchy bullous dermatosis, predominantly involving the extremities, which revealed a dermal infiltrate rich in eosinophils, C3 deposits at the dermalepidermal junction, and circulating antibodies to BP180 antigen, confirming the diagnosis of bullous pemphigoid. He was initially treated with deflazacort 1 mg/kg/day, further increased to 2 mg/ kg/day, followed by reduction over seven weeks with complete clinical resolution within this period. We discuss epidemiology, etiology, relationship with vaccination, clinical features, and treatment of thisrelatively rare bullous dermatosis in the pediatric age. Read More

    Prognostic factors for mortality in patients with bullous pemphigoid: a meta-analysis.
    Arch Dermatol Res 2017 Mar 19. Epub 2017 Mar 19.
    Department of Dermatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, Beijing, 100730, China.
    Bullous pemphigoid (BP) is a chronic debilitating autoimmune blistering disease that frequently occurs in the elderly population. Previous studies have suggested a high morbidity and mortality associated with BP. However, relatively few studies have investigated prognostic factors of BP mortality, and they showed considerably various results. Read More

    Bullous pemphigoid.
    Autoimmun Rev 2017 May 8;16(5):445-455. Epub 2017 Mar 8.
    Department of Dermatology and Allergology, Ludwig Maximilian University, Munich, Germany; Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary.
    Bullous pemphigoid (BP) is the most common autoimmune bullous disorder which is characterized by autoantibodies against hemidesmosomal proteins of the skin and mucous membranes. Collagen XVII and dystonin-e have been identified as target antigens. BP affects mostly the elderly. Read More

    Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial.
    Lancet 2017 Mar 6. Epub 2017 Mar 6.
    Medical Research Council Clinical Trials Unit at University College London, London, UK.
    Background: Bullous pemphigoid is a blistering skin disorder with increased mortality. We tested whether a strategy of starting treatment with doxycycline gives acceptable short-term blister control while conferring long-term safety advantages over starting treatment with oral corticosteroids.

    Methods: We did a pragmatic, multicentre, parallel-group randomised controlled trial of adults with bullous pemphigoid (three or more blisters at two or more sites and linear basement membrane IgG or C3). Read More

    Dysregulation of mCD46 and sCD46 contribute to the pathogenesis of bullous pemphigoid.
    Sci Rep 2017 Dec 10;7(1):145. Epub 2017 Mar 10.
    Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
    Bullous pemphigoid (BP) is an autoimmune bullous disease caused by autoantibodies against BP180 in the epidermal basement membrane. Autoantibody-mediated complement activation is an important process in BP pathogenesis. CD46, a crucial complement regulatory protein in the complement activation, has been reported to be involved in several autoimmune diseases. Read More

    Signaling and targeted-therapy of inflammatory cells in epidermolysis bullosa acquisita.
    Exp Dermatol 2017 Mar 7. Epub 2017 Mar 7.
    Lübeck Institute of Experimental Dermatology and Department of Dermatology, University of Lübeck, Germany.
    Pemphigoid diseases (PD) are chronic and life-threating autoimmune diseases of the skin and mucous membranes. PD are characterized and caused by autoantibodies targeting components of the basement membrane. In the PD epidermolysis bullosa acquisita (EBA) the target autoantigen is type VII collagen. Read More

    Neurodegenerative disorders, bullous pemphigoid and psoriasis: a comparative study in ethnic Poles indicates that Parkinson's disease is more relevant to bullous pemphigoid.
    Postepy Dermatol Alergol 2017 Feb 7;34(1):42-46. Epub 2017 Feb 7.
    Autoimmune Blistering Dermatoses Section, Department of Dermatology, Poznan University of Medical Sciences, Poznan, Poland.
    Introduction: Bullous pemphigoid (BP) is an autoimmune blistering dermatosis of the elderly with autoimmunity to hemidesmosomal proteins, BP180 and BP230, which are expressed also in neuronal tissue.

    Aim: The aim here was to retrospectively compare the prevalence of neurodegenerative disorders (ND), particularly Parkinson's disease (PD), unspecified conditions manifesting as dementia and stroke, in two groups of ethnic Poles, with BP and with psoriasis (Ps), in order to obtain data whether BP is more prone to coexist with ND than Ps in the elderly. Psoriasis was chosen in this comparative study as it was considered to be a paradigm of cutaneous disease with systemic manifestations. Read More

    Accuracy of molecular diagnostics in pemphigus and bullous pemphigoid: comparison of commercial and modified mosaic indirect immunofluorescence tests as well as enzyme-linked immunosorbent assays.
    Postepy Dermatol Alergol 2017 Feb 7;34(1):21-27. Epub 2017 Feb 7.
    Autoimmune Blistering Dermatoses Section, Department of Dermatology, Poznan University of Medical Sciences, Poznan, Poland.
    Introduction: Pemphigus and bullous pemphigoid (BP) are identified by autoantibodies (abs) against desmoglein 1, 3 (DSG1/3) and BP180/BP230, respectively. A novel mosaic to indirect immunofluorescence (IIF) using purified BP180 recombinant proteins spotted on slide and transfected cells expressing BP230, DSG1, DSG3 is available. The commercial (IgG detection) and modified (IgG4 detection) mosaic for indirect immunofluorescence (IIFc - IIF commercial, IIFm - IIF modified) and IgG ELISAs were evaluated in pemphigus and bullous pemphigoid (BP) molecular diagnostics. Read More

    Non-bullous lesions as the first manifestation of bullous pemphigoid: A retrospective analysis of 181 cases.
    J Dermatol 2017 Mar 3. Epub 2017 Mar 3.
    Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China.
    The aim of the present study was to explore the clinical and histopathological characteristics and treatment of patients with bullous pemphigoid (BP) that initially manifested as non-bullous lesions and provide information for early diagnosis and improved treatment. Medical records of 491 cases of BP were collected. The clinical and histopathological characteristics, treatment and outcomes of patients who initially presented with non-bullous lesions (prodromal BP, PBP) were analyzed and compared with those from patients who initially presented with bullous lesions (classical BP, cBP). Read More

    Bullous Pemphigoid: A Review of its Diagnosis, Associations and Treatment.
    Am J Clin Dermatol 2017 Feb 28. Epub 2017 Feb 28.
    Laboratory of Dermatology, EA7319 Derm-I-C, University of Reims Champagne-Ardenne, 51 rue Cognacq Jay, 51095, Cedex, France.
    Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease in Western countries, and typically affects the elderly. BP is immunologically characterized by tissue-bound and circulating autoantibodies directed against either the BP antigen 180 (BP180, or BPAG2) or the BP antigen 230 (BP230, or BPAG1e), or even both, which are components of hemidesmosomes involved in the dermal-epidermal cohesion. Risk factors for BP include old age, neurologic diseases (dementia, Parkinson's disease, cerebrovascular disease), and some particular drugs, including loop diuretics, spironolactone and neuroleptics. Read More

    [Dermatoses and herpes superinfection: A retrospective study of 34 cases].
    Ann Dermatol Venereol 2017 Mar 24;144(3):176-181. Epub 2017 Feb 24.
    Service de dermatologie, hôpital Cochin, université Paris Descartes, Assistance publique-Hôpitaux de Paris (AP-HP), pavillon Tarnier, 89, rue d'Assas, 75006 Paris, France. Electronic address:
    Background: Although varicelliform Kaposi eruption is a well-known complication of dermatoses, it has not been widely investigated.

    Aim: To investigate features of dermatoses and herpes superinfection in patients hospitalized in a dermatology department.

    Patients And Methods: We performed a single-centre, retrospective study between 2008 and 2014 that included cases of Kaposi varicelliform eruptions defined by positive PCR of an unconventional site of herpetic recurrence in a setting of active dermatitis. Read More

    Gabapentin-Induced Bullous Pemphigoid.
    J Am Osteopath Assoc 2017 Mar;117(3):191-193
    Bullous pemphigoid is an autoimmune blistering dermatosis with separation of the epidermis from the dermis. This disease process is common among elderly patients and manifests with subepidermal vesicles and tense bullae. Patients with bullous pemphigoid are more likely to have also received a previous diagnosis of a neurologic disorder. Read More

    Increased frequency of multiple sclerosis among patients with bullous pemphigoid: a population-based cohort study on comorbidities anchored around the diagnosis of bullous pemphigoid.
    Br J Dermatol 2017 Feb 24. Epub 2017 Feb 24.
    Department of Dermatology, Aarhus University Hospital, PP Oerumsgade 11, 8000, Aarhus C, Denmark.
    Background: Bullous pemphigoid (BP) is a disease of the elderly and may be associated with neurological and cardiovascular diseases and diabetes. Mortality rates strongly exceed those of the background population.

    Objectives: To investigate the frequency of comorbidities and their temporal relation to BP. Read More

    Three case reports of post immunization and post viral Bullous Pemphigoid: looking for the right trigger.
    BMC Pediatr 2017 Feb 23;17(1):60. Epub 2017 Feb 23.
    Dipartimento di Pediatria 1, Ospedale Infantile Regina Margherita, Regina Margherita Children's Hospital, Citta' della Salute e della Scienza di Torino, Piazza Polonia 94, 10126, Turin, Italy.
    Background: Bullous pemphigoid (BP) is a blistering skin disorder infrequent in infancy and rarely reported in medical literature.

    Case Presentation: Here we describe three cases of BP which were referred to our department in the last 15 years. Two of them developed an eruption of bullous lesions just a few days after vaccination for diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and Haemophilus influenzae B. Read More

    Bullous pemphigoid arising in a patient with acquired perforating dermatosis.
    Clin Exp Dermatol 2017 Feb 20. Epub 2017 Feb 20.
    Department of Dermatology, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.
    A middle-aged Japanese man who had been on haemodialysis treatment for diabetic nephropathy developed multiple itchy papules and nodules, which were histopathologically diagnosed as acquired perforating dermatosis. Two years later he developed oral lesions and subsequently numerous erosive plaques with necrotic crusts on the trunk and extremities. Histopathology of a papule showed a parakeratotic plug intermingled with basophilic, necrotic debris and collagen bundles, along with penetration of collagen bundles across the epidermis and subepidermal blister. Read More

    Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression.
    Clin Exp Dermatol 2017 Apr 16;42(3):309-312. Epub 2017 Feb 16.
    Department of Dermatology, Rambam Health Care Campus, Technion, Institute of Technology, Haifa, Israel.
    Bullous pemphigoid (BP) is considered to be a humorally mediated autoimmune disease, but autoreactive T-cells and T-regulatory cells (Tregs) have also been implicated in this disease. Tregs and the programmed death-1 (PD-1) : programmed death ligand (PD-L) pathway are both critical in terminating immune response, and elimination of either can result in breakdown of tolerance and development of autoimmunity. We report a patient with metastatic malignant melanoma (MM), who underwent pembrolizumab (anti-PD-1) therapy following unsuccessful treatment with ipilimumab [anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4]. Read More

    The Inpatient Burden of Autoimmune Blistering Disease in US Children: Analysis of Nationwide Inpatient Sample Data.
    Am J Clin Dermatol 2017 Apr;18(2):287-297
    Departments of Dermatology, Preventive Medicine and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Suite 1600, 676 N. St. Clair St., Chicago, IL, 60611, USA.
    Background: Little is known about the epidemiology of pediatric autoimmune blistering disorders (PAIBD).

    Objective: We sought to determine the inpatient burden and comorbidities of PAIBD.

    Methods: We analyzed data from the Nationwide Inpatient Sample from 2002 to 2012, which contained a representative 20% sample of all US hospitalizations. Read More

    Measuring of quality of life in autoimmune blistering disorders in Poland. Validation of disease - specific Autoimmune Bullous Disease Quality of Life (ABQOL) and the Treatment Autoimmune Bullous Disease Quality of Life (TABQOL) questionnaires.
    Adv Med Sci 2017 Feb 13;62(1):92-96. Epub 2017 Feb 13.
    Department of Dermatology and Immunodermatology, Medical University of Warsaw, Warsaw, Poland.
    Purpose: Autoimmune bullous dermatoses (AIBD) are rare, severe diseases resulting from some antibodies activity against the different adhesion structures within the skin and/or mucosa. Few studies investigated quality of life (QOL) in AIBD by generic and dermatology-specific instruments, all reporting strong impact on QOL. Recently, disease-specific measurement tools have been developed: Autoimmune Bullous Disease Quality of Life (ABQOL) and Treatment of Autoimmune Bullous Disease Quality of Life (TABQOL) questionnaires. Read More

    Polymorphism in the ABCB1 gene is associated with the risk of bullous pemphigoid in a polish population.
    J Dtsch Dermatol Ges 2017 Feb 16. Epub 2017 Feb 16.
    Department of Dermatology and Venereology, Chair of Dermatology and Venereology, Medical University of Lodz, Łódź, Poland.
    Background And Objectives: Polymorphisms in the P-glycoprotein-encoding ABCB1 gene may affect the intracellular concentration of xenobiotics, and thus contribute to the development of autoimmune diseases, including bullous pemphigoid (BP). The objective of the present study was to investigate whether there is an association between the C3435T and G2677T/A polymorphisms in the ABCB1 gene and the risk of BP in a Polish population.

    Patients And Methods: The study included 71 patients with BP and 156 healthy volunteers. Read More

    Questioning the specificity and sensitivity of ELISA for bullous pemphigoid diagnosis.
    Cutis 2017 Jan;99(1):E27-E30
    Department of Dermatology, Rutgers-Robert Wood Johnson Medical School, Somerset, New Jersey, USA.
    The reported sensitivity and specificity of enzyme-linked immunosorbent assay (ELISA) for bullous pemphigoid (BP) diagnosis is approximately 87% and 98%, respectively. These statistics suggest that ELISA is a reliable diagnostic test; therefore, the use of ELISA for BP diagnosis has increased. We report the case of a man who was diagnosed with BP and was treated for 3 years based on a positive ELISA for IgG against BP180. Read More

    Evidence for a role of eosinophils in blister formation in bullous pemphigoid.
    Allergy 2017 Jan 30. Epub 2017 Jan 30.
    Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
    Background: Bullous pemphigoid (BP) is an autoimmune bullous disease of the skin characterized by subepidermal blister formation due to tissue-bound and circulating autoantibodies to the hemidesmosomal antigens BP180 and BP230. Although eosinophils and their toxic mediators are found abundantly in BP lesions, their role in blister formation has remained unclear.

    Objective: To investigate the role of eosinophils in the pathogenesis of BP with a specific focus on blister formation and to define conditions inducing dermal-epidermal separation (DES). Read More

    Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features.
    Am J Dermatopathol 2017 Feb;39(2):121-129
    *Department of Pathology, Section of Dermatopathology, The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of †Dermatology, and ‡Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
    Immunotherapy targeting the programmed cell death 1 (PD-1) receptor has demonstrated tremendous promise in the treatment of advanced solid tumors. Dermatologic toxicities, however, are an emerging consequence of this therapy and have been clearly associated with immune checkpoint blockade antibodies. Distinctive clinical and histologic subtypes of dermatologic toxicity secondary to immunotherapy are emerging and include rare autoimmune bullous reactions (eg, bullous pemphigoid) and lichenoid eruptions. Read More

    1 OF 94